Enhancement of in vitro effects of polymeric nanoparticle encapsulated tamoxifin compared to tamoxifen in MCF-7 breast cancer cell line

Tamoxifen (TMX) is one of the common hormone therapies for breast cancer treatments. It acts as an anti-estrogen on breast cancer tissues by inducing apoptosis which is regulated by a variety of cellular signalling pathways such as tumour suppressor protein p53 and caspase-9. However, it is associat...

Full description

Bibliographic Details
Main Author: Tung, En En
Format: Thesis
Language:English
Published: 2012
Subjects:
Online Access:http://psasir.upm.edu.my/id/eprint/26742/
http://psasir.upm.edu.my/id/eprint/26742/1/FPSK%28m%29%202012%2030R.pdf
_version_ 1848845658524483584
author Tung, En En
author_facet Tung, En En
author_sort Tung, En En
building UPM Institutional Repository
collection Online Access
description Tamoxifen (TMX) is one of the common hormone therapies for breast cancer treatments. It acts as an anti-estrogen on breast cancer tissues by inducing apoptosis which is regulated by a variety of cellular signalling pathways such as tumour suppressor protein p53 and caspase-9. However, it is associated with side effects at high doses. This suggests the use of nanoparticles (NP) to deliver a lower dose of TMX with an enhance efficiency. Thus, the objective of this research was to assess and compare the in vitro effects of synthesized polymeric NP-encapsulated TMX to TMX toward MCF-7 breast cancer cell line. NP composed mainly of N-isopropylacrylamide (NIPAAm) were synthesized and loaded with TMX. Photon Cross Correlation Spectroscopy Nanophox (PCCS-Nanophox), Transmission Electron Microscopy (TEM), and Fourier Transform Infrared Spectroscopy (FTIR) were used to determine the size, morphology and infrared spectrum of the NP, respectively. The drug release pattern of the NP was investigated through dialysis. To study the cytotoxicity properties, MTT assay was performed on breast cancer cell line, MCF-7. The apoptotic effects were determined qualitatively through acradine orange and propidium iodide (AO/PI) stains with fluorescent microscopy, and quantitatively through FITC Annexin V and PI staining with flow cytometry. The expression levels of tumour suppressor protein p53 and caspase-9 were determined through ELISA. Finally, the data collected were analyzed by One Way Analysis of Variance (ANOVA), Tukey’s test. In this study, the polymeric NP were successfully prepared by gamma irradiation, forming spherical NP at a size of 49.89 ± 0.55 nm in diameter. TEM images showed that the particles were spherical in shape with a distinct core-shell structure. It was demonstrated that the void polymeric NP were non-toxic, and were able to release the drug in a sustained manner with 50.99 ± 1.21 % entrapment efficiency, underscoring the potential of these NP as a carrier for drugs. The proliferation of MCF-7 cells was significantly inhibited by the TMX-NP with a lower 50% inhibitory concentration (IC50) value of 24.63 ± 1.56 μM at 48 hr. It also possessed a greater apoptotic effect, resulting in a percentage of 68.53 ± 3.81% at 32.0 μM. Furthermore, higher levels of p53 (23.22 ± 2.79 U/ml) and caspase-9 (85.35 ± 11.11ng/ml) were detected in a dose-dependent manner. In conclusion, the therapeutic effects of the synthesized TMX NP were enhanced when compared to TMX. Its potential is not limited to anti-cancer drugs, but may also be applied in other drugs and diseases.
first_indexed 2025-11-15T08:50:19Z
format Thesis
id upm-26742
institution Universiti Putra Malaysia
institution_category Local University
language English
last_indexed 2025-11-15T08:50:19Z
publishDate 2012
recordtype eprints
repository_type Digital Repository
spelling upm-267422017-11-10T05:33:01Z http://psasir.upm.edu.my/id/eprint/26742/ Enhancement of in vitro effects of polymeric nanoparticle encapsulated tamoxifin compared to tamoxifen in MCF-7 breast cancer cell line Tung, En En Tamoxifen (TMX) is one of the common hormone therapies for breast cancer treatments. It acts as an anti-estrogen on breast cancer tissues by inducing apoptosis which is regulated by a variety of cellular signalling pathways such as tumour suppressor protein p53 and caspase-9. However, it is associated with side effects at high doses. This suggests the use of nanoparticles (NP) to deliver a lower dose of TMX with an enhance efficiency. Thus, the objective of this research was to assess and compare the in vitro effects of synthesized polymeric NP-encapsulated TMX to TMX toward MCF-7 breast cancer cell line. NP composed mainly of N-isopropylacrylamide (NIPAAm) were synthesized and loaded with TMX. Photon Cross Correlation Spectroscopy Nanophox (PCCS-Nanophox), Transmission Electron Microscopy (TEM), and Fourier Transform Infrared Spectroscopy (FTIR) were used to determine the size, morphology and infrared spectrum of the NP, respectively. The drug release pattern of the NP was investigated through dialysis. To study the cytotoxicity properties, MTT assay was performed on breast cancer cell line, MCF-7. The apoptotic effects were determined qualitatively through acradine orange and propidium iodide (AO/PI) stains with fluorescent microscopy, and quantitatively through FITC Annexin V and PI staining with flow cytometry. The expression levels of tumour suppressor protein p53 and caspase-9 were determined through ELISA. Finally, the data collected were analyzed by One Way Analysis of Variance (ANOVA), Tukey’s test. In this study, the polymeric NP were successfully prepared by gamma irradiation, forming spherical NP at a size of 49.89 ± 0.55 nm in diameter. TEM images showed that the particles were spherical in shape with a distinct core-shell structure. It was demonstrated that the void polymeric NP were non-toxic, and were able to release the drug in a sustained manner with 50.99 ± 1.21 % entrapment efficiency, underscoring the potential of these NP as a carrier for drugs. The proliferation of MCF-7 cells was significantly inhibited by the TMX-NP with a lower 50% inhibitory concentration (IC50) value of 24.63 ± 1.56 μM at 48 hr. It also possessed a greater apoptotic effect, resulting in a percentage of 68.53 ± 3.81% at 32.0 μM. Furthermore, higher levels of p53 (23.22 ± 2.79 U/ml) and caspase-9 (85.35 ± 11.11ng/ml) were detected in a dose-dependent manner. In conclusion, the therapeutic effects of the synthesized TMX NP were enhanced when compared to TMX. Its potential is not limited to anti-cancer drugs, but may also be applied in other drugs and diseases. 2012-05 Thesis NonPeerReviewed application/pdf en http://psasir.upm.edu.my/id/eprint/26742/1/FPSK%28m%29%202012%2030R.pdf Tung, En En (2012) Enhancement of in vitro effects of polymeric nanoparticle encapsulated tamoxifin compared to tamoxifen in MCF-7 breast cancer cell line. Masters thesis, Universiti Putra Malaysia. Breast Neoplasms - drug therapy Tamoxifen - therapeutic use
spellingShingle Breast Neoplasms - drug therapy
Tamoxifen - therapeutic use
Tung, En En
Enhancement of in vitro effects of polymeric nanoparticle encapsulated tamoxifin compared to tamoxifen in MCF-7 breast cancer cell line
title Enhancement of in vitro effects of polymeric nanoparticle encapsulated tamoxifin compared to tamoxifen in MCF-7 breast cancer cell line
title_full Enhancement of in vitro effects of polymeric nanoparticle encapsulated tamoxifin compared to tamoxifen in MCF-7 breast cancer cell line
title_fullStr Enhancement of in vitro effects of polymeric nanoparticle encapsulated tamoxifin compared to tamoxifen in MCF-7 breast cancer cell line
title_full_unstemmed Enhancement of in vitro effects of polymeric nanoparticle encapsulated tamoxifin compared to tamoxifen in MCF-7 breast cancer cell line
title_short Enhancement of in vitro effects of polymeric nanoparticle encapsulated tamoxifin compared to tamoxifen in MCF-7 breast cancer cell line
title_sort enhancement of in vitro effects of polymeric nanoparticle encapsulated tamoxifin compared to tamoxifen in mcf-7 breast cancer cell line
topic Breast Neoplasms - drug therapy
Tamoxifen - therapeutic use
url http://psasir.upm.edu.my/id/eprint/26742/
http://psasir.upm.edu.my/id/eprint/26742/1/FPSK%28m%29%202012%2030R.pdf